ArticleRegenerative engineering and translational medicine2025
Sustained Delivery of Chondrogenic Molecules Using Sugar Glass Nanoparticle-Integrated Fibrous Scaffolds for Cartilage Tissue Engineering.
Article in Regenerative engineering and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Purpose: Biomaterial scaffolds capable of controlled release of bioactive molecules hold significant potential in tissue engineering, offering a promising avenue to enhance tissue regeneration. They provide localized and sustained delivery of biological cues to direct stem cell differentiation while creating a three-dimensional microenvironment that supports cell adhesion and growth. Methods: In this study, we utilized reverse micelle sugar glass nanoparticles (SGnPs), previously developed by our team, to encapsulate the chondrogenic growth factor TGFB1. This approach aimed to preserve the bioactivity of these molecules before their release. The TGFB1-SGnPs were directly incorporated into electrospun fibrous scaffolds, engineered specifically to ensure the sustained release of the growth factor during the culture of human bone marrow-derived mesenchymal stem/stromal cells (BMSCs). Results: TGFB1 was released in a sustained manner over 39 days from TGFB1-SGnP-incorporated fibrous scaffolds, made from poly (ε-caprolactone), poly (d-lactic acid) (PLA), and poly (lactic-co-glycolic acid). Among these formulations, the PLA-based scaffolds demonstrated the highest cumulative TGFB1 release over the study period. In vitro cell studies demonstrated that TGFB1-SGnP-PLA fibrous scaffolds supported the proliferation of BMSCs and enhanced chondrogenic differentiation. Transcript expression analysis of BMSCs seeded on TGFB1-SGnP-PLA fibrous scaffolds induced for chondrogenesis revealed an upregulation of chondrocyte-associated markers, including Conclusion: This study demonstrates the potential of using SGnPs to protect and deliver chondrogenic induction molecules from electrospun fibrous scaffolds in a sustained manner, promoting the chondrogenic differentiation of BMSCs in cartilage tissue engineering.Lay Summary.Researchers have developed advanced biomaterial scaffolds that release bioactive molecules to enhance tissue regeneration. These "smart scaffolds" provide a three-dimensional environment for cell growth and localized cues to support biological functions. Utilizing sugar glass nanoparticles (SGnPs) to encapsulate growth factors like TGFB1, electrospun fibrous scaffolds incorporating TGFB1-SGnPs were crafted to assess their effectiveness in supporting the activity of human bone marrow-derived mesenchymal stem/stromal cells (BMSCs). Results showed that TGFB1, particularly from TGFB1-SGnP-PLA scaffolds, significantly promoted BMSC proliferation and chondrogenic differentiation, as evidenced by increased markers associated with cartilage cells. This innovative approach demonstrates considerable potential for advancing cartilage tissue engineering and offers a new therapeutic strategy for conditions such as osteoarthritis, enhancing tissue repair and regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.